Lack of association between expression of MRP2 and early relapse of colorectal cancer in patients receiving FOLFOX‑4 chemotherapy

R MalekzadehF BishehsariM MahdaviniaR AnsariEpidemiology and molecular genetics of colorectal cancer in Iran: a reviewArch Iran Med12161169200919249887

A SadjadiM NouraieMA MohagheghiA Mousavi-JarrahiR MalekzadehDM ParkinCancer occurrence in Iran in 2002: an international perspectiveAsian Pac J Cancer Prev6359363200516236000

V CatalanoAM BaldelliP GiordaniS CascinuMolecular markers predictive of response to chemotherapy in gastrointestinal tumorsCrit Rev Oncol Hematol3893104200110.1016/S1040-8428(00)00114-111311657

WT BeckCircumvention of multidrug resistance with anti-P-glycoprotein antibodies: clinical potential or experimental artifact?J Natl Cancer Inst877375199510.1093/jnci/87.2.73

M TakanoR YumotoT MurakamiExpression and function of efflux drug transporters in the intestinePharmacol Ther109137161200610.1016/j.pharmthera.2005.06.00516209890

GE SanduskyKS MintzeSE PrattAH DantzigExpression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarraysHistopathology416574200210.1046/j.1365-2559.2002.01403.x

R KerbS HoffmeyerU BrinkmannABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2Pharmacogenomics25164200110.1517/14622416.2.1.5111258197

R OhashiF TakahashiR CuiInteraction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cellCancer Lett252225234200710.1016/j.canlet.2006.12.02517276588

K TaniguchiM WadaK KohnoA human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulationCancer Res56412441291996

E BakosR EversE SinkóA VáradiP BorstB SarkadiInteractions of the human multidrug resistance proteins MRP1 and MRP2 with organic anionsMol Pharmacol57760768200010727523

E CasadoJ De CastroC Belda-IniestaMolecular markers in colorectal cancer: genetic bases for a customised treatmentClin Transl Oncol9549554200710.1007/s12094-007-0102-817921101

S GiacchettiB PerpointR ZidaniPhase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancerJ Clin Oncol181361472000

WL AllenVM CoylePG JohnstonPredicting the outcome of chemotherapy for colorectal cancerCurr Opin Pharmacol6332336200610.1016/j.coph.2006.02.00516750422

CA RabikME DolanMolecular mechanisms of resistance and toxicity associated with platinating agentsCancer Treat Rev33923200710.1016/j.ctrv.2006.09.00617084534

K ZhangP MackKP WongGlutathione-related mechanisms in cellular resistance to anticancer drugsInt J Oncol1287188219989499449

Y ItohM TamaiK YokogawaInvolvement of multidrug resistance-associated protein 2 in in vivo cisplatin resistance of rat hepatoma AH66 cellsAnticancer Res2216491653200212168849

B LiedertV MaternaD SchadendorfJ ThomaleH LageOverexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatinJ Invest Dermatol121172176200310.1046/j.1523-1747.2003.12313.x12839578

K ShenD CuiL SunM HanJ LiuInhibition of IGF-IR increases chemosensitivity in human colorectal cancer cells through MRP-2 promoter suppressionJ Cell BiochemJan242012(Epub ahead of print)

LH SobinC WittekindInternational Union Against CancerTNM Classification of Malignant Tumors6th editionJohn Wiley & SonsNew Jersey2002

HJ ArtsD KatsarosEG de VriesDrug resistance associated markers P-glycoprotein, multidrug resistance associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinomaClin Cancer Res5279828051999

R UshijimaK TakayamaUM IzumiImmunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancerAnticancer Res2743514358200718214043

T AndréC BoniL Mounedji-BoudiafOxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancerN Engl J Med350234323512004

E HinoshitaT UchiumiK TaguchiIncreased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomasClin Cancer Res6240124072000

P BorstR EversM KoolJ WijnholdsA family of drug transporters: the multidrug resistance-associated proteinsJ Natl Cancer Inst9212951302200010.1093/jnci/92.16.129510944550

M YamasakiT MakinoT MasuzawaRole of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinomaBr J Cancer104707713201110.1038/sj.bjc.660607121206495

GB Van den BroekM WildemanCR RaschMolecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiationInt J Cancer12426432650200919253368

A MaciejczykE JagodaT WysockaR MatkowskiB GyörffyH LageP SurowiakABCC2 (MRP2, cMOAT) localized in the nuclear envelope of breast carcinoma cells correlates with poor clinical outcomePathol Oncol Res18331342201210.1007/s12253-011-9449-921986666